Medicure to pay MGI $19M for Aggrastat
Medicure has agreed to pay MGI Pharma $19 million for the U.S. marketing rights to Aggrastat injection for coronary syndrome. The drug garnered $10.9 million in U.S. sales last year. Aggrastat was launched in 1998 and is available in 82 countries.
- see the press release for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
